Ganglioside G(D2) specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma

N. K.V. Cheung, H. Lazarus, F. D. Miraldi, C. R. Abramowsky, S. Kallick, U. M. Saarinen, T. Spitzer, S. E. Strandjord, P. F. Coccia, N. A. Berger

Research output: Contribution to journalArticle

312 Citations (Scopus)

Abstract

The murine IgG3 monoclonal antibody (MoAb) 3F8, specific for the ganglioside G(D2), activates human complement, is active in antibody-dependent cell-mediated cytotoxicity (ADCC) and can target specifically to human neuroblastoma in patients with metastatic disease. In a phase I study, 3F8 was administered intravenously (IV) to 17 patients with metastatic G(D2) positive neuroblastoma or malignant melanoma at doses of 5, 20, 50, and 100 mg/m2. Serum 3F8 levels achieved were proportional to the dose of 3F8 infused. However, serum antimouse antibody levels did not increase with the amount of 3F8 administered. Toxicities included pain, hypertension, urticaria, and complement depletion. All acute side effects were controllable with symptomatic therapy. No long-term side effects were detected in patients observed for more than 14 months. None of the 17 patients received any antitumor therapy postantibody treatment. Antitumor responses occurred in seven of 17 patients. These ranged from complete clinical remissions to mixed responses. The murine monoclonal antibody (MoAb) 3F8 has clinically utility for the diagnosis and therapy of neuroblastoma and melanoma.

Original languageEnglish (US)
Pages (from-to)1430-1440
Number of pages11
JournalJournal of Clinical Oncology
Volume5
Issue number9
DOIs
StatePublished - Jan 1 1987

Fingerprint

Gangliosides
Neuroblastoma
Melanoma
Monoclonal Antibodies
Antibody-Dependent Cell Cytotoxicity
Urticaria
Therapeutics
Serum
Immunoglobulin G
Hypertension
Pain
Antibodies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cheung, N. K. V., Lazarus, H., Miraldi, F. D., Abramowsky, C. R., Kallick, S., Saarinen, U. M., ... Berger, N. A. (1987). Ganglioside G(D2) specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma. Journal of Clinical Oncology, 5(9), 1430-1440. https://doi.org/10.1200/JCO.1987.5.9.1430

Ganglioside G(D2) specific monoclonal antibody 3F8 : A phase I study in patients with neuroblastoma and malignant melanoma. / Cheung, N. K.V.; Lazarus, H.; Miraldi, F. D.; Abramowsky, C. R.; Kallick, S.; Saarinen, U. M.; Spitzer, T.; Strandjord, S. E.; Coccia, P. F.; Berger, N. A.

In: Journal of Clinical Oncology, Vol. 5, No. 9, 01.01.1987, p. 1430-1440.

Research output: Contribution to journalArticle

Cheung, NKV, Lazarus, H, Miraldi, FD, Abramowsky, CR, Kallick, S, Saarinen, UM, Spitzer, T, Strandjord, SE, Coccia, PF & Berger, NA 1987, 'Ganglioside G(D2) specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma', Journal of Clinical Oncology, vol. 5, no. 9, pp. 1430-1440. https://doi.org/10.1200/JCO.1987.5.9.1430
Cheung, N. K.V. ; Lazarus, H. ; Miraldi, F. D. ; Abramowsky, C. R. ; Kallick, S. ; Saarinen, U. M. ; Spitzer, T. ; Strandjord, S. E. ; Coccia, P. F. ; Berger, N. A. / Ganglioside G(D2) specific monoclonal antibody 3F8 : A phase I study in patients with neuroblastoma and malignant melanoma. In: Journal of Clinical Oncology. 1987 ; Vol. 5, No. 9. pp. 1430-1440.
@article{7a908d296dfb476592ed1d8f6b468d38,
title = "Ganglioside G(D2) specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma",
abstract = "The murine IgG3 monoclonal antibody (MoAb) 3F8, specific for the ganglioside G(D2), activates human complement, is active in antibody-dependent cell-mediated cytotoxicity (ADCC) and can target specifically to human neuroblastoma in patients with metastatic disease. In a phase I study, 3F8 was administered intravenously (IV) to 17 patients with metastatic G(D2) positive neuroblastoma or malignant melanoma at doses of 5, 20, 50, and 100 mg/m2. Serum 3F8 levels achieved were proportional to the dose of 3F8 infused. However, serum antimouse antibody levels did not increase with the amount of 3F8 administered. Toxicities included pain, hypertension, urticaria, and complement depletion. All acute side effects were controllable with symptomatic therapy. No long-term side effects were detected in patients observed for more than 14 months. None of the 17 patients received any antitumor therapy postantibody treatment. Antitumor responses occurred in seven of 17 patients. These ranged from complete clinical remissions to mixed responses. The murine monoclonal antibody (MoAb) 3F8 has clinically utility for the diagnosis and therapy of neuroblastoma and melanoma.",
author = "Cheung, {N. K.V.} and H. Lazarus and Miraldi, {F. D.} and Abramowsky, {C. R.} and S. Kallick and Saarinen, {U. M.} and T. Spitzer and Strandjord, {S. E.} and Coccia, {P. F.} and Berger, {N. A.}",
year = "1987",
month = "1",
day = "1",
doi = "10.1200/JCO.1987.5.9.1430",
language = "English (US)",
volume = "5",
pages = "1430--1440",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - Ganglioside G(D2) specific monoclonal antibody 3F8

T2 - A phase I study in patients with neuroblastoma and malignant melanoma

AU - Cheung, N. K.V.

AU - Lazarus, H.

AU - Miraldi, F. D.

AU - Abramowsky, C. R.

AU - Kallick, S.

AU - Saarinen, U. M.

AU - Spitzer, T.

AU - Strandjord, S. E.

AU - Coccia, P. F.

AU - Berger, N. A.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - The murine IgG3 monoclonal antibody (MoAb) 3F8, specific for the ganglioside G(D2), activates human complement, is active in antibody-dependent cell-mediated cytotoxicity (ADCC) and can target specifically to human neuroblastoma in patients with metastatic disease. In a phase I study, 3F8 was administered intravenously (IV) to 17 patients with metastatic G(D2) positive neuroblastoma or malignant melanoma at doses of 5, 20, 50, and 100 mg/m2. Serum 3F8 levels achieved were proportional to the dose of 3F8 infused. However, serum antimouse antibody levels did not increase with the amount of 3F8 administered. Toxicities included pain, hypertension, urticaria, and complement depletion. All acute side effects were controllable with symptomatic therapy. No long-term side effects were detected in patients observed for more than 14 months. None of the 17 patients received any antitumor therapy postantibody treatment. Antitumor responses occurred in seven of 17 patients. These ranged from complete clinical remissions to mixed responses. The murine monoclonal antibody (MoAb) 3F8 has clinically utility for the diagnosis and therapy of neuroblastoma and melanoma.

AB - The murine IgG3 monoclonal antibody (MoAb) 3F8, specific for the ganglioside G(D2), activates human complement, is active in antibody-dependent cell-mediated cytotoxicity (ADCC) and can target specifically to human neuroblastoma in patients with metastatic disease. In a phase I study, 3F8 was administered intravenously (IV) to 17 patients with metastatic G(D2) positive neuroblastoma or malignant melanoma at doses of 5, 20, 50, and 100 mg/m2. Serum 3F8 levels achieved were proportional to the dose of 3F8 infused. However, serum antimouse antibody levels did not increase with the amount of 3F8 administered. Toxicities included pain, hypertension, urticaria, and complement depletion. All acute side effects were controllable with symptomatic therapy. No long-term side effects were detected in patients observed for more than 14 months. None of the 17 patients received any antitumor therapy postantibody treatment. Antitumor responses occurred in seven of 17 patients. These ranged from complete clinical remissions to mixed responses. The murine monoclonal antibody (MoAb) 3F8 has clinically utility for the diagnosis and therapy of neuroblastoma and melanoma.

UR - http://www.scopus.com/inward/record.url?scp=0023525839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023525839&partnerID=8YFLogxK

U2 - 10.1200/JCO.1987.5.9.1430

DO - 10.1200/JCO.1987.5.9.1430

M3 - Article

C2 - 3625258

AN - SCOPUS:0023525839

VL - 5

SP - 1430

EP - 1440

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -